Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition.
The clinical trial included five COVID-19 patients, three in severe condition and two in critical condition. All five patients had complete recovery from their respective severe/critical condition and were released from the hospital after an average of 5.5 days (severe) and 8.5 days (critical), following administration of Allocetra, at which time they were all COVID-19 PCR negative. There were no reported severe adverse events relating to the administration of Allocetra in the patients, and the therapy was well-tolerated.
https://www.enlivex.com/investor-relations/#latest-news
https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=7&b=2380&ID=93761&m=rl
АПДЕЙТ: Запустили вторую фазу испытаний
https://clinicaltrials.gov/ct2/show/NCT04590053
АПДЙТ-2: Первые два пациента получили препарат
https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=7&b=2380&ID=93966&m=rl
https://s3.amazonaws.com/b2icontent.irpass.cc/2380/rl93966.pdf
